ArticleInternational journal of retina and vitreous2025
Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye.Ophthalmology and therapy · 2026Article
- Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.Ophthalmology and therapy · 2026Article
- Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion.Life (Basel, Switzerland) · 2026Article
- Faricimab: current evidence for the treatment of retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results.Journal of clinical medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaricimab, the new anti-vascular endothelial growth factor (VEGF) drug including a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has emerged as a therapeutic option for macular edema secondary to retinal vein occlusion (RVO), and its efficacy has been demonstrated in randomized controlled trials (RCTs); however, reports on its use in clinical practice are still limited. This study was conducted to evaluate the real-world treatment outcomes of faricimab for macular edema secondary to RVO, managed with a single initial injection plus pro re nata (1 + PRN) approach in both treatment-naïve and previously treated patients who switched to this regimen.
methodsThis retrospective observational study included patients diagnosed with branch or central RVO, who received intravitreal faricimab therapy following the 1 + PRN protocol. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed.
resultsThirty patients (17 naïve and 13 switched) were included. The number of IVF was 1.4 ± 0.7 and 2.4 ± 2.1, in the naïve and switch groups, respectively. The mean follow-up period was 3.7 ± 2.7 and 4.9 ± 2.9 months in the naïve and switch patients, respectively. Mean LogMAR BCVA improved in the naïve group from 0.30 ± 0.37 at baseline to 0.11 ± 0.20 (p = 0.01) at the final visit, while there was no significant difference between 0.45 ± 0.45 at baseline and 0.35 ± 0.37 at the final visit in the switch group (p = 0.19). CMT reduction was significant in both groups; from 442 ± 117 μm at baseline to 304 ± 57 μm at one month after final IVF (p < 0.0001) in the naïve group; and from 436 ± 170 μm at baseline to 285 ± 76 μm at one month after final IVF (p = 0.0002) in the switch group.
conclusionThe 1 + PRN faricimab regimen improves vision and reduces macular edema with a reduced injection burden in patients with RVO. These findings validated the real-world efficacy of faricimab and supported its use as a viable therapeutic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.